Introduction
============

Hyperlipidemia and hepatic steatosis are frequently found in the metabolic syndrome and type 2 diabetes ([@B16]; [@B26]). Hyperlipidemia is characterized as high T-CHO, TG, LDL, and low HDL levels ([@B29]), whilst hepatic steatosis is represented by high TG, T-CHO, AST, and ALT levels ([@B33]). Emerging evidence suggest that dyslipidemia is a significant risk factor for the development of type 2 diabetes ([@B1]; [@B2]), and pharmacological lipid-lowering therapy is effective to alleviate the complications of type 2 diabetes including hyperlipidemia, hepatic steatosis, coronary heart disease, etc. ([@B49]; [@B31]; [@B32]). *Cyclocarya paliurus* (Batal.) Iljinskaja (Juglandaceae) is a native medicinal plant grown in the southwest of China. The leaves of *C. paliurus* (CP) have been used as a herbal tea in China for its special flavor and the benefits to the obese and diabetic Chinese populations. The bioactive components isolated from CP are flavonoids, triterpenoids, organic acids, and polysaccharides, these components contribute to its versatile biological properties including antihyperglycemia, antihyperlipidemia, and antihypertension ([@B14]; [@B48]). Previous studies have investigated the anti-diabetic function and mechanism of CP leaves on STZ and high-fat diet-induced type 2 diabetic mice, and its potent hypoglycemic effect has been verified on diabetic mice ([@B37]; [@B22]). Moreover, CP has also been reported with hypolipidemic effects *in vivo* ([@B47]; [@B20]; [@B46]). However, the mechanism of bioactive constituents of CP on diabetic dyslipidemia remain unknown. Therefore, our objective is to study the effects of CP on lipid disorders in diabetes and elucidate its mechanism-of-actions.

It is acknowlegded that the majority of herbal medicines, including TCMs are orally delivered drugs of polypharmacy. Their active components are firstly absorbed into the bloodstream and then selectively and simultaneously interact with multiple targets at the root causes of the disease ([@B52]). Serum pharmacochemistry is a rapid and reliable method using the UPLC-MS technique to track the components absorbed into the bloodstream and has been widely used to reveal the efficacy of TCMs ([@B45]). Moerover, metabolomics is an approach to analyze the metabolites, the intermediate products of metabolic reactions of living systems. This technology contains many subclasses based on the chemical characteristics of metabolites, namely lipidomics, amino metabolomics, and sugar metabolomics, etc. It has been widely used in the evaluation of the therapeutic effects and elucidation of the therapeutic mechanisms of herbal products ([@B38]). Metabolomics profiling can reveal whole metabolic profile changes of living systems in response to endogenous or exogenous stimuli such as drug treatment ([@B4]). Because any effects of herbal products are mediated by their constituents in a complex biological system, metabolomics can help us to analyze their action network comprehensively. Network pharmacology is a bioinformatics strategy to understand drug action and mechanisms by mapping drug-target-disease networks from the biological level ([@B19]). To date, accumulating evidence suggest that network pharmacology approach is a powerful tool to study the molecular mechanisms of the complex components found in medicinal herbs.

Considering CP as a herbal tea with multiple components and diabetic dyslipidemia as a cluster of lipid abnormalities, we focused on the investigation of the beneficial effect of CP and its mechanisms against diabetic dyslipidemia using lipidomics, serum pharmacochemistry, and network pharmacology approaches.

Materials and Methods {#s1}
=====================

Chemicals and Materials
-----------------------

### Regents and Standards

UPLC grade organic solvent was purchased from Merck (Darmstadt, Germany). Deionized water was obtained from a milli-Q system (Millipore, Billerica, MA, United States). Formic acid, ammonium formate, and phosphoric acid were obtained from Sigma (St. Louis, MO, United States). Lipids standards including a lipids mixture of TG, CE, DG, PE, PC, and SM, etc, were purchased from Avanti Polar Lipid (Alabaster, AL, United States). Strptomycin and glibenclamide was purchased from Sigma (St. Louis, MO, United States).

### Plant Material Preparation

The leaves of *Cyclocarya paliurus* (Batal.) Iljinskaja were collected and authenticated by Prof. Hu-Biao Chen from School of Chinese Medicine, Hong Kong Baptist University, and voucher specimens (No. CP20151201) was stored in our Research Laboratory. For the preparation of the extract of *C. paliurus* leaves (CP extract), the dried leaves of *C. paliurus* (5 kg) were soaked in boiled water (1:10 *m/v*) for 2 h twice. The solution was concentrated and dried under vacuum freezer to obtain crude extract. The crude extract was then extracted by 70% EtOH for 2 h (1:10 m/v) in an ultrasound bath. The refined solution was concentrated and dried under vacuum freezer again and the refined extract was stored in 4°C fridge until use. CP solution was prepared with 0.5% sodium carboxymethyl cellulose (CMC-Na) solution for animal oral administration and MeOH for phytochemical analysis.

Animal Studies
--------------

### Animal Handling and Diets

Eight-week-old C57/BL6J mice were purchased from Laboratory Animal Services Centre, Chinese University of Hong Kong and raised in the Laboratory Animal Services Center, School of Chinese Medicine, Hong Kong Baptist University. The mice were raised in a 12 h light/dark cycle, temperature controlled (22°C) standard animal room provided with diet and water *ad libitum.* All experimental protocols were approved by the Animal Ethics Committees of Hong Kong Baptist University, in accordance with "Institutional Guidelines and Animal Ordinance" (Department of Health, Hong Kong Special Administrative Region) (Registration No. LIUYE/15-16/01-CLNC). Body weight, food consumption, and blood glucose level were monitored each week. Blood glucose level was determined by OMRON glucometer (Beijing, China) using blood samples collected from the tail vein.

### Animal Groups

The diabetes mice model was induced by high-fat diet (adjusted Calories Diet, 42% from fat) (No. 881372) (Harlan Laboratories, Inc., Indianapolis, IN, United States) for 4 weeks and intraperitoneal (*i.p*) injection with STZ (25 mg/kg) three times in following 3 days. The mice with fasting glucose level higher than 11 mmol/L were considered as diabetic mice, and the diabetic mice with consecutive 7-day hyperglycemia (11 mmol/L or greater) were used for the experiment. An equal volume of vehicle was injected into the control mice. The diabetic mice were then divided into the diabetic group (model group), the CP treatment group (CP group) and glibenclamide treatment group (positive group). For the CP treatment group, the mice were orally administrated 2 g/kg/day CP until end of the experiment according to previous experimental data (**Supplementary Figure [S1](#FS1){ref-type="supplementary-material"}**). The normal mice were divided into two groups: vehicle control group (0.5% CMC-Na solution treated, named as blank group) and CP-treated control group (CP treated, named as control group). CP-treated control group mice were orally administered 2 g/kg/day CP extract and blank group mice were orally administered same volume 0.5% CMC-Na solution as CP solution. Glibenclamide was given at 15 mg/kg/day in 0.5% CNC-Na solution to mice in positive group according to the previous study ([@B43]).

### Blood Sample Collection and Preparation

For serum pharmacochemistry study, mice were orally administered CP solution and anesthesia by 3% chloral hydrate through intraperitoneal injection after 10 mins. About 1 mL blood was collected in heparin-tube. Plasma was obtained after 3,000 rpm centrifuge for 30 min at room temperature. A total of 900 μL MeOH was added to 100 μL plasma and centrifuged at 14,000 for 10 min at 4°C to precipitate protein. A total of 800 μL supernatant was dried under vacuum concentrator within 30 min and dissolved in 200 μL 70% methanol for LC-MS analysis.

For lipidomics study, about 1 mL blood was collected from mice under anesthesia, serum was obtained after centrifuging at 3,000 rpm for 30 min at room temperature. A total of 50 μL serum was used for lipidomics study. Briefly, 250 μL Folch solvent with the internal standard was added in 50 μL serum and vortexed vigorously. Two phases were formed after centrifugation at 5,000 rpm for 15 min. The bottom layer was dried under vacuum concentrator and dissolved in 200 μL of ACN/IPA/H2O (65:30:5 v/v/v) for analysis.

Another 100 μL serum was used for clinical index analysis including ALT, AST, ALP, CREA and BUN using a biochemical analyzer (Hitachi 902 Automatic Analyzer; Hitachi, Japan). TG, TCHO, LDL, and HDL were analyzed using assay kits purchased from Nanjing Jiancheng Bioengineering Institute (Nanjing, China) according to the manufacturers' instructions.

### Hepatic Histopathology Analysis and Biochemical Analysis

At the end of the study, the mice were sacrificed, and liver tissue was collected for H&E staining to analyses histology changes. Liver tissue from sacrificed mice was soaked in 10% formalin solution (prepared by 1× phosphate-buffered saline, PBS) and fixed for 12 h. Samples were then made into paraffin sections as specimens and stained with hematoxylin and eosin (H&E) according to manufacturer's protocol (Mayer's Hematoxylin Solution, Sigma-Aldrich). The sections were observed and captured under microscopy. About other 50 mg liver tissues were homogenized in iced 1× PBS solution (1:10, *m/v*). The homogenized solution was used for TG and TCHO analysis following the protocol of Nanjing Jiancheng Bioengineering Institute (Nanjing, China).

Phytochemical and Metabolomics Study
------------------------------------

### Phytochemical Analysis

The chromatographic analysis was performed on an Agilent 1290 UPLC system equipped with an autosampler, binary gradient pump, and PDA detector. The system was operated at 30°C and a water ACQUITY UPLC HSS T3 column (150 mm × 2.1 mm, 1.7 μm) was used. The injection volume was 5 μL and the mobile phase flow rate was 0.4 mL/min. Solvents that constituted the mobile phase were (A) 0.2% aqueous acetic acid and (B) acetonitrile. The elution conditions were as follows: 0--5 min, linear gradient 2--5% B; 5--10 min, linear gradient 5--10% B; 10--15 min, linear gradient 10--25% B; 15--25 min, linear gradient 25--40% B; 25--28 min, linear gradient 40--90% B. Peaks were detected at 254 nm. The compounds of CP extracts were characterized by retention time, MS/MS information and related chemical standards in positive and negative modes.

### Lipidomics Study

The liquid chromatogram was performed on an Agilent 1290 UPLC system. A waters ACQUITY UPLC HSS C18 column (2.1 mm × 100 mm, 1.8 μm particle size) was used for separation. The column temperature was maintained at 40°C and autosampler temperature was maintained at 8°C. The separation was performed with mobile phase A and B within 20 min per sample. Phase A consists of 60:40 water/ACN in 10 mM ammonium formate and 0.1% formic acid, and phase B is made by 90:10 IPA/ACN with 10 mM ammonium formate and 0.1% formic acid. The linear gradient was as follow: 32% B (0--1.5 min); 32--45% B (1.5--4 min); 45--52% B (4--5 min); 52--58% B (5--8 min); 58--66% B (8--11 min); 66--70% B (11--14 min); 70--75% B (14--18 min); 75--97% B (18--21 min); maintain 97% B (21--25 min); decrease to 32% B (25--30 min); maintained at 32% B ([@B9]). The injection volume is 2 μL for the positive mode and 6 μL for the negative mode.

XCMS package in R was used to convert chromatograms intensity into raw data for multivariate statistical analysis using metaboanalyst ([@B11]). For lipid identification, the frame *m/z* values were used to search information on LIPID MAPS, Human Metabolome Database (HMDB) and Metlin database. The matches were confirmed by lipids' exact tandem mass (MS/MS) and retention time based on our internal standards (SPLASH^TM^ Lipidomix^®^ Mass Spec Standard, Avanti Polar Lipids, United States).

Bioinformatics and Statistical Analysis
---------------------------------------

### Potential Targets Prediction and Linking Analysis

The detected chemical components of CP in plasma after oral administration were imported into our in-house target prediction tool "MOST" ([@B12]) to construct the target prediction database. Targets from the prediction database were then used to determine the relevance with diabetic dyslipidemia with literature review, and the relevant genes were considered as CP targets for diabetic dyslipidemia. The lipids data were imported into Cytoscape to generate a metabolites-reaction-enzyme-gene database. The genes of significantly changed lipids in CP treatment group were considered as lipid targets of CP. The predicted targets and lipids targets of CP were combined together to upload to STRING ([@B36]) for PPIs analysis to link the action of predicted targets with lipids targets of CP.

### Target-Diabetic Dyslipidemia Link Analysis

All determined and predicted targets were searched on PubMed using key words: \[targets name\] AND \[diabetes\] AND \[lipidemia\]. The targets which were studied on lipid disorders in diabetes were also included.

### Statistical Analysis

GraphPad was used for statistical analysis of the biochemical data. Statistically significant differences (*p* \< 0.05) in mean values were calculated by Student's *t*-test or one-way ANOVA. The lipidomics data was processed by R package with XCMS. Metaboanalyst ([@B42]) was used for multivariate statistical analysis. Cytoscape was used trace associated gene-enzyme using KEGG database.

Results
=======

CP Attenuated Diabetic Dyslipidemia in Diabetic Mice Induced by High Fat Diet and STZ
-------------------------------------------------------------------------------------

As shown in **Table [1](#T1){ref-type="table"}**, after high fat diet and STZ treatment, blood glucose levels of mice were significantly elevated whereas their body weight was significantly demoted compared with control and blank group, indicating that the diabetic mice model was well established. In contrast, those clinical signs were significantly rescued after CP treatment for 5 weeks. Since both hyperlipidemia and hepatic steatosis are characterized as substantial lipid disorders in diabetes, we determined serum TCHO, LDL, HDL, and TG levels, and hepatic AST, ALT, TG, and TCHO levels. Liver histopathological changes were also monitored. As shown in **Figure [1](#F1){ref-type="fig"}** and **Supplementary Figure [S4](#FS1){ref-type="supplementary-material"}**, compared to that of control and blank group, serum TG, TCHO, and LDL levels, as well as hepatic AST, ALT, TG, and TCHO levels of the model group were significantly increased, whereas serum HDL levels were significantly decreased, indicating that the hyperlipidemia and hepatic steatosis were developed in the model group. In CP or glibenclamide-treated groups, those altered lipids-associated indexes were significantly alleviated. In addition, histological examination of hepatic sections also revealed that there were a large number of vesicles of fat accumulating within hepatocytes of diabetic mice, which was significantly reduced after CP or glibenclamide treatment. These results suggested that CP extract has a great potential to attenuate diabetic dyslipidemia and hepatic steatosis induced by high fat diet and STZ in mice.

###### 

Blood glucose (mM) levels and body weight changes on week 0, 3, and 5.

                           Blank        Control      Model                CP                Positive
  ------------------------ ------------ ------------ -------------------- ----------------- -----------------
  **Blood glucose (mM)**                                                                    
  Week 0                   6.8 ± 1.2    6.1 ± 0.9    17.0 ± 3.5^\#\#\#^   16.2 ± 4.3        16.5 ± 5.2
  Week 3                   6.7 ± 1.0    6.6 ± 1.4    17.5 ± 4.0^\#\#\#^   12.7 ± 3.2^∗^     12.6 ± 3.5^∗^
  Week 5                   6.0 ± 1.0    5.1 ± 0.5    16.6 ± 3.0^\#\#\#^   10.7 ± 1.5^∗∗∗^   10.4 ± 2.0^∗∗∗^
  **Body weight (g)**                                                                       
  Week 0                   23.8 ± 0.8   23.5 ± 1.8   24.4 ± 1.0           24.4 ± 1.0        24.5 ± 0.9
  Week 3                   24.6 ± 1.0   25.0 ± 1.0   23.4 ± 1.8^\#^       24.1 ± 0.3        23.9 ± 1.3
  Week 5                   26.3 ± 1.2   26.2 ± 1.3   23.2 ± 1.8^\#\#^     24.9 ± 0.6^∗^     24.6 ± 1.2^∗^
                                                                                            

The effects of CP extract on blood glucose levels and body weight of diabetic mice. All data are presented as means

±

SD. Diabetic model group vs. control group:

\#

p \< 0.05,

\#\#

p \< 0.01 and

\#\#\#

p \< 0.001. CP or glibenclamide (positive) treatment group vs. diabetic model group:

∗

p \< 0.05,

∗∗

p \< 0.01,

∗∗∗

p \< 0.001.

![*Cyclocarya paliurus* attenuated diabetic dyslipidemia and hepatic steatosis induced by high fat diet and STZ in mice. Blank: non-diabetic control group; Control: CP-treated non-diabetic control group; Model: STZ and high fat diet-induced diabetic model group; CP: CP treated model group; Positive: glibenclamide treated model group. **(A--F)** Serum TG, TCHO, HDL, LDL, AST, and ALT level. **(G)** Histology analysis of liver tissues by **H,E** staining. **(H,I)** Liver TG and TCHO level. All data are presented as means + SEM (*n* = 6∼8). ^\#^*p* \< 0.05, ^\#\#^*p* \< 0.01, ^\#\#\#^*p* \< 0.001 (comparison between control and model group); ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, ^∗∗∗^*p* \< 0.001 (comparison between CP group, positive group, and model group).](fphar-09-00973-g001){#F1}

CP Improved Circulating Lipid Metabolism in Diabetic Dyslipidemia
-----------------------------------------------------------------

To study the CP effect on lipid metabolism in diabetic mice, we performed a lipidomics study on mice serum. Fatty acyls (fatty acids), glycerolipids (DG and TG), glycerophospholipids (PC, PE, and PI), and sphingolipids (SM) were then used for multivariate statistical analysis as shown in **Supplementary Table [S1.1](#TS1){ref-type="supplementary-material"}**. As the PCA and PLS-DA are two effective multivariate analysis methods for large-scale data matrix, the combining data were analyzed using PCA and PLS-DA approaches. As shown in **Figures [2A,B](#F2){ref-type="fig"}**, PCA and PLS-DA score showed a clear classification between model group and control group, demonstrating that circulating lipids profiles are significantly different in the model group. As well, the CP-treated group or glibenclamide treated group also had its own distinctive classification, bearing some overlap. Considering the overlap between model group and CP-treated group, we further narrowed down the profiles of lipids in these two groups using OPLS-DA method. Notably, CE, DG, TG, PC, and SM were significantly distinguished between these two groups (**Figures [2C,D](#F2){ref-type="fig"}**), And then, we applied the hierarchal clustering analysis to segregate the lipid metabolites into three distinct groups (shown in **Figure [2E](#F2){ref-type="fig"}**). A significant number of lipids were up-regulated in model group in comparison with control or blank groups. After CP or glibenclamide treatment, the levels of these lipids were greatly down-regulated. The results suggest that CP or glibenclamide could significantly regulate lipid metabolism in diabetes. Interestingly, PCA and PLS-DA analysis result showed that the score plot of CP-treated group and glibenclamide-treated group were not separated, and the same result was observed in heat map of hierarchal clustering analysis (**Figures [2B,E](#F2){ref-type="fig"}**), suggesting CP and glibenclamide may share the similar metabolic pathways to improve the diabetic dyslipidemia.

![The lipidomics study on serum from diabetic mice: Metabolic profiles and multivariate data analysis. **(A)** PCA score plot of the blank group (red color), control group (green color), model group (dark blue), CP group (light blue), and positive group (purple). **(B)** PLS-DA score plot with 95% confidence interval of all studied groups. **(C,D)** OPLS-DA score plot and S-plot between model group and CP treatment group. **(E)** Heatmap of selected metabolites was built based on one-way ANOVA rankings and hierarchical clustering. Each dot represents one mouse.](fphar-09-00973-g002){#F2}

Subsequently, we analyzed the changes of lipids between control (blank) groups and model groups, and found that 47 lipids were elevated and 53 lipids were reduced in model group. After CP treatment, 30 lipids including CE, DG, TG, PC, and SM species were significantly either up-regulated or down-regulated (*p* \< 0.05) (**Figure [3](#F3){ref-type="fig"}**). After importing those CP-regulated lipids to Cytoscape, a network pathway was built based on KEGG database and revealed that metabolic pathways including arachidonic acid metabolism, bile acid biosynthesis, *de novo* fatty acid biosynthesis, glycerophospholipid metabolism, glycosphingolipid metabolism, linoleate metabolism and saturated fatty acids beta-oxidation are involved in the regulating function of CP in lipid metabolism (As shown in **Supplementary Figure [S5](#FS2){ref-type="supplementary-material"}**).

![*Cyclocarya paliurus* improved circulating lipids profiles in diabetic mice model. **(A)** Cholesterol ester (CE), **(B)** Diglyceride (DG); **(C)** Triglyceride (TG); **(D)** Sphingomyelin (SM); **(E)** Phosphatidylcholines (GP-PC); **(F)** Phosphatidylinositol (PI); **(G)** Phosphatidylethanolamine (GP-PE); **(H)** Lysophosphatidylethanolamine (GP-LPE). All data are presented as means ± SEM (*n* = 6∼8). ^\#^*p* \< 0.05, ^\#\#^*p* \< 0.01, ^\#\#\#^*p* \< 0.001 (comparison between control and model group); ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, ^∗∗∗^*p* \< 0.001 (comparison between CP group and model group).](fphar-09-00973-g003){#F3}

CP Possess Multiple Components-Multiple Targets-Multiple Pathways Properties for Diabetic Dyslipidemia
------------------------------------------------------------------------------------------------------

Since absorption into the bloodstream is one of the prerequisites for drug efficacy, we performed a pharmacochemistry study to detect the CP components in blood stream after oral administration in mice. As shown in **Table [2](#T2){ref-type="table"}** and **Supplementary Figure [S2](#FS1){ref-type="supplementary-material"}**, after oral administration of CP to normal C57/BL6 mice, 13 compounds in total: quinic acid, neochlorogenic acid, chlorogenic acid, 4-hydroxybenzoic acid, gallic acid, quercetin-3-glucuronide, kaempferol, loganin 7-pentoside, astragalin, kaempferol-3-rhamnoside, quercetin, quadranoside IV, and asiatic acid were detected. Subsequently, we used in-house tools "MOST: most-similar ligand-based approach to target prediction" ([@B12]) to predict the protein targets of major potential active components of CP identified in bloodstream as shown in **Supplementary Table [S1.2](#TS1){ref-type="supplementary-material"}**. Sixty-nine targets were matched for flavonoids, 59 targets were matched for organic acids, and 2 targets were matched for saponins. There targets were searched by related key words online to determine the relevance of diabetic dyslipidemia. Five targets were selected after reference searching. Finally, we linked the lipids targets with predicted targets using STRING ([@B36]) to build interaction networks of predicted targets and lipids targets via PPI. Among these compounds, the main predicted targets of CP were ALOX12, APP, BCL2, CYP2C9, and PTPN1 while the predicted-targets linked lipids targets via PPI analysis were PLA2G(s) and PI3K(s) families as shown in **Supplementary Figure [S3](#FS1){ref-type="supplementary-material"}**.

###### 

Constituents of CP identified in plasma.

  No.   Compound                  Classification   Blank plasma   Plasma after 10 min administration   Plasma after 30 min administration
  ----- ------------------------- ---------------- -------------- ------------------------------------ ------------------------------------
  1     Quinic acid               Organic acid     --             √                                    √
  2     Neochlorogenic acid       Organic acid     --             √                                    --
  3     Chlorogenic acid          Organic acid     --             √                                    √
  4     4-Hydroxybenzoic acid     Organic acid     --             √                                    √
  5     Gallic acid               Organic acid     --             √                                    --
  6     Quercetin-3-glucuronide   Flavonoid        --             √                                    √
  7     Astragalin                Flavonoid        --             √                                    √
  8     Kaempferol                Flavonoid        --             √                                    √
  9     Loganin 7-pentoside       Flavonoid        --             √                                    √
  10    Kaempferol-3-rhamnoside   Flavonoid        --             √                                    √
  11    Quercetin                 Flavonoid        --             √                                    √
  12    Quadranoside IV           Saponin          --             √                                    √
  13    Asiatic acid              Saponin          --             √                                    √
                                                                                                       

We then conducted reference searching to review the experiment study on these targets as shown in **Supplementary Table [S2](#TS2){ref-type="supplementary-material"}**. The ALOX, BCL-2, CYP 2C9, PLA2G(s) and PI3K(s) families, PLD2 and PTEN were determined as quercetin and kaempferol targets on diabetic dyslipidemia ([@B10]). PTPN1, PI3K(s) family and PLD2 were determined as targets of saponins such as quadranoside IV and asiatic acid ([@B28]), whilst BCL-2, PI3K(s) family, PLD2 and PTEN were determined as action targets of gallic acid and 4-hydrobenzoic acids (**Figure [4](#F4){ref-type="fig"}**).

![*Cyclocarya paliurus* possess multiple components-multiple targets-multiple pathways properties for diabetic dyslipidemia. **Left** to **right:** The predicted targets based on CP constituents. The PPI network of predicted targets-linked lipid targets. The lipids regulated by CP in diabetic dyslipidemia.](fphar-09-00973-g004){#F4}

Discussion
==========

Hyperlipidemia is the most common form of dyslipidemia, refers to the abnormally elevated levels of any/all lipids or lipoproteins in the blood, frequently happened in long-term type II diabetes patients ([@B7]). Recent studies have indicated that diabetic dyslipidemia may not only be the consequence but also the cause of disturbed glucose metabolism ([@B24]). Recently, CP was reported to improve insulin sensitivity ([@B15]), attenuates inflammation ([@B39]), and control hyperglycemic and hyperlipidemic abnormalities ([@B44]) both *in vitro* and *in vivo*, although the hypolipidemic mechanism has not been elucidated yet. In this study, we confirmed CP alleviated lipid dysfunction in diabetes, particularly diabetic dyslipidemia, as revealed by the clinical index, histological analysis, and lipidomics analysis. Mechanistically, we employed a network pharmacology approach to determine that CP's hypolipidemic effect involvement in PI3K and MAPK signaling pathways.

Lipidomics is a powerful tool to investigate lipid profiles changes. Previous studies indicated that circulating lipidomes were correlated with hyperlipidemia and hepatic steatosis ([@B40]), therefore making lipids profiles an adequate indicator of CP effects in this study. Through the lipidomics study, it was shown that STZ and high-fat diet induced type 2 diabetic mice had lipid disorders due to lipid metabolism changes. Among the changed lipids, the majority lipids classes were DG, TG, CE, PC, SM, FA, PI, and PE. We found that CE, DG, TG, SM, PC, PI, and LPE were increased in the model group, while PE was decreased in the model group. CE is a dietary lipid involved in fat digestion and absorption as well as cholesterol metabolism. It directly affects LDL as well as HDL levels, and can be hydrolyzed by pancreatic enzymes to produce cholesterol and free fatty acids ([@B30]). DG and TG represent the main lipid components of fat deposits, which accumulated largely in lipid droplets of hepatocytes when in hepatic steatosis ([@B35]). Our results showed that CE, DG, and TG were downregulated after CP treatment which further indiacates the reduxction in fat accumulation in lipid droplets. PC (lecithin) are one class of glycerophospholipids with choline as a head group, which constitute major component of biological membranes, associating with the health benefits such as liver repair and lipolysis ([@B25]). Lipid absorption and utilization, particularly TG, is closely related to the PC content and its associated enzymes. Besides, PC can protect against steatosis in mice ([@B23]). Our results displayed that CP could reduce the palmitic acids levels and adjust PC content to improve lipid utilization and protect hepatic steatosis. PE is directly associated with diabetes and dyslipidemia and PC/PE ratio is closely correlated with the accumulation of hepatic TG content ([@B5]; [@B21]). Our results showed that the levels of PE were elevated in CP-treated diabetic mice, indicating CP can reduce TG accumulation. SM contains either PC or PE as its head group. As lipid rafts, SM takes part in lipid microdomains and inhibition of SM synthesis would increase the ceramide level, a mediator of non-alcoholic fatty liver diseases ([@B17]). Our results showed that PC could increase SM content by reducing ceramide levels, possibly to alleviate hepatic steatosis. Our results indicate that CP has a great potential in the improvement of circulating lipid metabolism in diabetic dyslipidemia.

The beneficial function of CP on diabetic dyslipidemia can be deduced by its lipid regulating effect on circulatory system through multiple metabolic pathways. Therefore, it is important to identify the CP components and elucidate their biological activities to further define its use as a herbal product. Moreover, identifying the targets of CP's active components can lead to greater understanding of CP's mechanisms of action against diabetic dyslipidemia. By using lipidomics-based network pharmacology approach, we determined several CP targets for diabetic dyslipidemia based on its potential active components. Besides of ACP1, ALDH2, BCL2, and CA2 targets, the ALOX15, CYP2C9, and PTPN1 targets can interact with lipid targets PLD2, PTEN, PLA2G(s), and PI3K(s) family targets. BCL2, PTPN1, and PI3K alters expression of PI3K signaling pathway ([@B27]; [@B34]). ALDH2, ALOX15, and BCL2 are involved in MAPK signaling pathway ([@B6]; [@B50]; [@B51]), and activation of MAPK can influence the expression of CYP2C9 ([@B3]). PLD2, and its product phosphatidic acid, can also activate MAPK ([@B8]). Therefore, the signaling pathway for its pharmacological mechanism may be related with PI3K and MAPK signaling pathway ([@B22]; [@B41]; [@B43]). The multiple components of CP targeting multiple targets through multiple metabolic pathways to improve diabetic dyslipidemia in type 2 diabetic mice.

To our knowledge, we have provided a novel metabolomics-based network pharmacology approach to combine and link experimental targets and predicted targets together based on the bioactive components of herbal products. For a network pharmacology study, particularly on herbal medicine or herbal formula, the metabolomics-based network pharmacology strategy can integrate more comprehensive targets for targets prediction and linking their interactions. Integrating the analysis of systemic metabolic profiles based on metabolomics study with computational prediction based on serum pharmacochemistry information can result in more precise pharmacological mechanism associated targets prediction ([@B13]). It is also the first study to link lipids targets from lipidomics study with predicted targets from computational tools through PPI to improve the network pharmacology analysis. Up to now, there are some questions that still need to be answered: First, some of PPI between predicted targets and lipid targets have not been validated experimentally. Further experimental work can be performed to uncover the relationship between targets-targets. Next, the potential active compounds we identified in this study have been shown to be effective for anti-diabetic studies on animals, the systemic evaluation of combinatorial use on these compounds have not been conducted yet. Additional *in vitro* and *in vivo* studies in future will help to uncover the multiple pharmacological mechanisms found in herbal medicines.

Conclusion
==========

In this study, we report CP attenuated diabetic dyslipidemia and hepatic streatosis in high fat diet and STZ-induced diabetic mice. The lipidomics study revealed CP improves circulatory lipids disorder, and the serum pharmacochemistry study revealed quinic acid, neochlorogenic acid, chlorogenic acid, 4-hydroxybenzoic acid, gallic acid, quercetin-3-glucuronide, kaempferol, loganin 7-pentoside, astragalin, kaempferol-3-rhamnoside, quercetin, quadranoside IV, and asiatic acid are potential active components of CP. Combining lipidomics and bioinformatics analysis, ALOX12, APP, BCL2, CYP2C9, and PTPN1 were predicted as direct targets of CP, whilst PLD2, PTEN and PLA2G(s) and PI3K(s) families were predicted as lipids linked targets of CP in diabetic hyperlipidemia. In conclusion, the CP was shown to be a multi-component and multi-targets herbal product with potent lipid regulation properties in dyslipidemia.
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ALP

:   alkaline phosphatase

ALT

:   alanine aminotransferase

AST

:   aspartate aminotransferase

BUN

:   urea nitrogen

CE

:   cholesterol ester

CP

:   *Cyclocarya paliurus*

CREA

:   creatinine

DG

:   diglyceride

HDL

:   high-density lipoproteins

LDL

:   low-density lipoproteins

PC

:   phosphatidylcholine

PE

:   phosphatidylethanolamine

PPI

:   protein--protein interaction

SM

:   sphingomyelin

STZ

:   streptozotocin

T-CHO

:   total cholesterol

TG

:   total triglyceride
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